• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对抑制阿尔茨海默氏症肽聚集的化合物的高通量筛选。

A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide.

作者信息

Kim Woojin, Kim Yunkyoung, Min Jaeki, Kim Dong Jin, Chang Young-Tae, Hecht Michael H

机构信息

Department of Chemistry, Princeton University, Princeton, New Jersey 08544, USA.

出版信息

ACS Chem Biol. 2006 Aug 22;1(7):461-9. doi: 10.1021/cb600135w.

DOI:10.1021/cb600135w
PMID:17168524
Abstract

Aggregation of the Alzheimer's peptide Abeta produces toxic multimeric species that play a key role in the development of Alzheimer's disease. Compounds that inhibit this aggregation may prove useful as therapeutic agents for the prevention or treatment of Alzheimer's disease. Although aggregation inhibitors may already exist in combinatorial libraries, finding these compounds in a cost-effective high-throughput manner poses an enormous challenge. To meet this challenge, we have developed a novel high-throughput screen capable of isolating inhibitors of Abeta aggregation from large libraries of inactive candidates. The screen uses a fusion of Abeta42 to GFP. In the absence of inhibition, the rapid misfolding and aggregation of Abeta42 causes the entire fusion protein to misfold, thereby preventing fluorescence. Compounds that inhibit Abeta42 aggregation enable GFP to fold into its native structure and be identified by the resulting fluorescent signal. By implementing the screen on a pilot library of triazine derivatives, we have identified several putative inhibitors. One of the selected compounds was studied in detail by a series of biochemical and biophysical methods. These studies confirmed that the selected compound inhibits aggregation of synthetic Abeta42 peptide. The fluorescence-based method described here is rapid and inexpensive and can be used to screen large libraries for inhibitors of Abeta42 aggregation and/or amyloidogenesis.

摘要

阿尔茨海默病肽β-淀粉样蛋白(Aβ)的聚集会产生有毒的多聚体,这些多聚体在阿尔茨海默病的发展中起关键作用。抑制这种聚集的化合物可能被证明是预防或治疗阿尔茨海默病的有用治疗剂。尽管组合文库中可能已经存在聚集抑制剂,但以具有成本效益的高通量方式找到这些化合物面临着巨大挑战。为了应对这一挑战,我们开发了一种新型高通量筛选方法,能够从大量无活性候选物文库中分离出Aβ聚集抑制剂。该筛选方法使用Aβ42与绿色荧光蛋白(GFP)的融合蛋白。在没有抑制作用的情况下,Aβ42的快速错误折叠和聚集会导致整个融合蛋白错误折叠,从而阻止荧光产生。抑制Aβ42聚集的化合物能使GFP折叠成其天然结构,并通过产生的荧光信号进行鉴定。通过在三嗪衍生物的先导文库上实施该筛选,我们鉴定出了几种假定的抑制剂。其中一种选定的化合物通过一系列生化和生物物理方法进行了详细研究。这些研究证实,选定的化合物能抑制合成Aβ42肽的聚集。这里描述的基于荧光的方法快速且廉价,可用于筛选大型文库以寻找Aβ42聚集和/或淀粉样蛋白生成的抑制剂。

相似文献

1
A high-throughput screen for compounds that inhibit aggregation of the Alzheimer's peptide.针对抑制阿尔茨海默氏症肽聚集的化合物的高通量筛选。
ACS Chem Biol. 2006 Aug 22;1(7):461-9. doi: 10.1021/cb600135w.
2
Mutations that reduce aggregation of the Alzheimer's Abeta42 peptide: an unbiased search for the sequence determinants of Abeta amyloidogenesis.降低阿尔茨海默病β淀粉样蛋白42肽聚集的突变:对β淀粉样蛋白生成序列决定因素的无偏搜索。
J Mol Biol. 2002 Jun 21;319(5):1279-90. doi: 10.1016/S0022-2836(02)00399-6.
3
Conversion of Abeta42 into a folded soluble native-like protein using a semi-random library of amphipathic helices.利用两亲性螺旋的半随机文库将 Abeta42 转化为折叠的可溶性天然样蛋白。
J Mol Biol. 2010 Mar 12;396(5):1284-94. doi: 10.1016/j.jmb.2009.12.019. Epub 2009 Dec 21.
4
Probing Alzheimer amyloid peptide aggregation using a cell-free fluorescent protein refolding method.利用无细胞荧光蛋白重折叠方法探究阿尔茨海默病淀粉样肽聚集
Biochem Cell Biol. 2009 Aug;87(4):631-9. doi: 10.1139/o09-038.
5
A plant cell-based system that predicts aβ42 misfolding: potential as a drug discovery tool for Alzheimer's disease.基于植物细胞的预测 Aβ42 错误折叠系统:作为阿尔茨海默病药物发现工具的潜力。
Mol Genet Metab. 2012 Nov;107(3):571-9. doi: 10.1016/j.ymgme.2012.08.010. Epub 2012 Aug 18.
6
Mutagenesis of the central hydrophobic cluster in Abeta42 Alzheimer's peptide. Side-chain properties correlate with aggregation propensities.β淀粉样蛋白42(Abeta42)中中央疏水簇的诱变。侧链性质与聚集倾向相关。
FEBS J. 2006 Feb;273(3):658-68. doi: 10.1111/j.1742-4658.2005.05102.x.
7
Discovery of amyloid-beta aggregation inhibitors using an engineered assay for intracellular protein folding and solubility.利用一种用于细胞内蛋白质折叠和溶解性的工程化检测方法发现β-淀粉样蛋白聚集抑制剂。
Protein Sci. 2009 Feb;18(2):277-86. doi: 10.1002/pro.33.
8
Abeta40 protects non-toxic Abeta42 monomer from aggregation.淀粉样前体蛋白40(Abeta40)可保护无毒的淀粉样前体蛋白42(Abeta42)单体不发生聚集。
J Mol Biol. 2007 Jun 15;369(4):909-16. doi: 10.1016/j.jmb.2007.04.014. Epub 2007 Apr 12.
9
High-throughput analysis of Alzheimer's beta-amyloid aggregation using a microfluidic self-assembly of monomers.利用单体的微流体自组装对阿尔茨海默病β-淀粉样蛋白聚集进行高通量分析。
Anal Chem. 2009 Apr 1;81(7):2751-9. doi: 10.1021/ac802701z.
10
Biotin-avidin interaction-based screening assay for Alzheimer's beta-peptide oligomer inhibitors.
Anal Biochem. 2006 Sep 15;356(2):265-72. doi: 10.1016/j.ab.2006.04.036. Epub 2006 May 11.

引用本文的文献

1
Optimization of a High-Throughput Screen for Monitoring Disease-Associated Protein Misfolding and Aggregation in Bacteria.用于监测细菌中疾病相关蛋白质错误折叠和聚集的高通量筛选的优化
ACS Synth Biol. 2025 Jun 20;14(6):2283-2293. doi: 10.1021/acssynbio.5c00166. Epub 2025 May 12.
2
1,3,5-Triazine: A Promising Molecular Scaffold for Novel Agents for the Treatment of Alzheimer's Disease.1,3,5-三嗪:一种用于治疗阿尔茨海默病新型药物的有前景的分子骨架。
Int J Mol Sci. 2025 Jan 21;26(3):882. doi: 10.3390/ijms26030882.
3
A protein aggregation platform that distinguishes oligomers from amyloid fibrils.
一种能够区分低聚物和淀粉样纤维的蛋白质聚集平台。
Analyst. 2023 May 16;148(10):2283-2294. doi: 10.1039/d3an00487b.
4
Aβ and Tau Prions Causing Alzheimer's Disease.β淀粉样蛋白和 Tau 朊病毒导致阿尔茨海默病。
Methods Mol Biol. 2023;2561:293-337. doi: 10.1007/978-1-0716-2655-9_16.
5
Multi-Target Effects of Novel Synthetic Coumarin Derivatives Protecting Aβ-GFP SH-SY5Y Cells against Aβ Toxicity.新型合成香豆素衍生物的多靶点作用保护 Aβ-GFP SH-SY5Y 细胞免受 Aβ 毒性的影响。
Cells. 2021 Nov 9;10(11):3095. doi: 10.3390/cells10113095.
6
Metallohelices emulate the properties of short cationic α-helical peptides.金属螺旋模拟短阳离子α-螺旋肽的特性。
Chem Sci. 2021 Jan 13;12(5):1620-1631. doi: 10.1039/d0sc06412b.
7
A Luminescence-Based System for Identification of Genetically Encodable Inhibitors of Protein Aggregation.一种基于发光的系统,用于鉴定蛋白质聚集的基因可编码抑制剂。
ACS Omega. 2020 May 29;5(22):12974-12978. doi: 10.1021/acsomega.0c00779. eCollection 2020 Jun 9.
8
Advances in protein misfolding, amyloidosis and its correlation with human diseases.蛋白质错误折叠、淀粉样变性及其与人类疾病的相关性研究进展。
3 Biotech. 2020 May;10(5):193. doi: 10.1007/s13205-020-2166-x. Epub 2020 Apr 4.
9
Bacterial production and direct functional screening of expanded molecular libraries for discovering inhibitors of protein aggregation.细菌生产和直接功能筛选扩展分子文库以发现蛋白质聚集抑制剂。
Sci Adv. 2019 Oct 16;5(10):eaax5108. doi: 10.1126/sciadv.aax5108. eCollection 2019 Oct.
10
Utilizing split-NanoLuc luciferase fragments as luminescent probes for protein solubility in living cells.利用分裂型纳米荧光素酶片段作为活细胞中蛋白质溶解度的发光探针。
Methods Enzymol. 2019;622:55-66. doi: 10.1016/bs.mie.2019.02.003. Epub 2019 Mar 9.